Current stock page

Catalysts

NBIX Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

NBIXNeurocrine Biosciences, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$167.40−$2.00 (−1.18%)

Latest quote

  • Momentum
    70
  • Value
    77
  • Quality
    79
  • Risk resilience
    69
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 10, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 74/100

Momentum 70/100 and sentiment — before the next covered event.

Recent coverage
4 articles

Updated Nov 15, 2026 · Sentiment 7.67%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 70/100AIQ Edge 9/10 Strong Relative Position
Beat rate
75%
6 of 8 reported periods
Average surprise
+12.7%
Across covered historical reports
Latest result
+72.3%
Nov 2, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 2, 2026—$1.91$3.29+72.3%$1.04B$1.12B
Jul 30, 2026—$1.85$2.85+54.1%$890.33M$959M
May 5, 2026—$1.22$1.91+56.6%$768.25M$814.5M
Feb 11, 2026—$1.80$1.88+4.4%$790.5M$805.5M
Oct 28, 2025—$1.58$2.04+29.1%$806.8M$794.9M
Jul 30, 2025—$0.98$1.06+8.2%$746.41M$687.5M
May 5, 2025—$0.54$0.08-85.0%$559.63M$572.6M
Feb 6, 2025—$1.62$1.00-38.3%$629.44M$627.7M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
25
Buy
4
Hold
12-month analyst target
$206.80
+23.54% versus current price
Based on 29 analyst observations. Targets are estimates, not predictions.
Low target
$183.00
+9.32% vs latest price
Average target
$206.80
+23.54% vs latest price
High target
$224.00
+33.81% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 10, 2027

Next known earnings or reporting date.

EPS estimate$2.07

Current analyst expectation for the upcoming report.

Revenue estimate$1.09B

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score70

Where event reaction would show up first.

AIQ score74/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
29
Average target
$206.80
Target upside
23.54%
Target range
$183.00 - $224.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
1
Neutral
2
Negative
1
seekingalpha.com · Nov 5, 2026

Neurocrine Biosciences Stock: Breaking Down A Solid Quarter (NASDAQ:NBIX)

Neurocrine Biosciences posts strong Q3 earnings as INGREZZA drives growth and rare disease expansion gains traction. Find out why NBIX stock is a buy.

seekingalpha.com · Nov 4, 2026

Neurocrine Biosciences: 3 Growth Drivers And An Attractive Valuation (NASDAQ:NBIX)

Neurocrine Biosciences offers growth and value with strong INGREZZA sales, new drug momentum, and 2027 catalysts. Learn more about NBIX stock here.

seekingalpha.com · Nov 4, 2026

Neurocrine Biosciences, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:NBIX) 2026-11-04

2026-11-04. The following slide deck was published by Neurocrine Biosciences, Inc.

insidermonkey.com · Sep 18, 2026

Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story

On August 12, Neurocrine Biosciences (NASDAQ:NBIX) published something unusual for a psychiatric drug: proof that patients feel the difference, not just that a clinician's scale says they moved less.

Open full news and sentiment

NBIX Catalysts FAQ

What are the next catalysts for NBIX stock?

NBIX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move NBIX stock?

Upcoming events that could move NBIX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could NBIX's next earnings report affect the stock?

NBIX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive NBIX stock higher?

NBIX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt NBIX stock?

NBIX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.